Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
How did EVAX's recent EPS compare to expectations?
The most recent EPS for Evaxion A/S is $-0.5, beating expectations of $-0.3.
How did Evaxion A/S EVAX's revenue perform in the last quarter?
Evaxion A/S revenue for the last quarter is $-0.5
What is the revenue estimate for Evaxion A/S?
According to 4 of Wall street analyst, the revenue estimate of Evaxion A/S range from $0.0 to $0.0
What's the earning quality score for Evaxion A/S?
Evaxion A/S has a earning quality score of B/43.09247. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Evaxion A/S report earnings?
Evaxion A/S next earnings report is expected in 2026-08-05
What are Evaxion A/S's expected earnings?
Evaxion A/S expected earnings is $0.0, according to wall-street analysts.
Did Evaxion A/S beat earnings expectations?
Evaxion A/S recent earnings of $0.0 does not beat expectations.